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Basal cell carcinoma (BCC) is a malignant neoplasm derived from nonkeratinizing cells that originate from the basal layer of
the epidermis and is the most frequent type of skin cancer in humans, with cumulative exposure to ultraviolet radiation as an
important risk factor. BCC occurs most frequently at sun-exposed sites, with the head and neck being common areas. Tumors
can be classiﬁed as nodular, superﬁcial, morpheaform, inﬁltrating, metatypic, and ﬁbroepithelioma of Pinkus. Several treatment
optionssuch as surgical excision and nonsurgicalprocedures are available. The choice of treatment should be determined based on
the histological subtype of a lesion, cost, its size and location, patient age, medical condition of the patient, treatment availability,
and the patient’s wishes. The aim of any therapy selected for BCC treatment involving the head and neck is to ensure complete
removal, the preservation of function, and a good cosmetic outcome.
1.Introduction
Basal cell carcinoma (BCC) is deﬁned by the World Health
Organization Committee on the histological typing of
skin tumors as “a locally invasive, slowly spreading tumor
which rarely metastasize, arising in the epidermis or hair
follicles and in which, in particular, the peripheral cells
usually simulate the basal cells of the epidermis” [1].
BCC constitutes approximately 75% of nonmelanoma skin
cancers. It is usually observed in older patients, especially
in those frequently and intensively exposed to ultraviolet
radiation during their lives. The most typical site of BCC
is uncovered skin directly exposed to the sun. Thus, BCC
is often observed in head and neck areas, especially the
eyelid and nose. It occurs chieﬂy in the elderly and is
more common in males. Generally speaking, the tumor
grows slowly and behaves in a nonaggressive fashion. BCC
may be treated by surgery, cryotherapy, radiotherapy, and
curettage and electrodessication [2]. Other less frequently
used treatment modalities include the topical application
of 5-ﬂuorouracil (5-FU) ointment, laser treatment, and
systemic chemotherapy [3] .T oa c h i e v eaf a v o r a b l eo u t c o m e ,
itisimportant torecognizethehistologicalsubtypes,identify
the anatomic locations that can increase the risk of spread,
and understand the limitations of all available treatment
modalities. If surgical defects are repaired, it is necessary to
carefully plan the reconstruction after the tumor margins
have been cleared. This paper discusses the histopathology,
clinical presentation, and management of BCC of the head
and neck. Local ﬂaps for reconstruction of surgical defects
are also described.
2.Etiology
The role of sunlight as a causative factor in cutaneous
carcinoma is further reﬂected in its geographic distribution.
There are more cases in southern compared to northern
areas of the United States [4]. Individuals with more darkly
p i g m e n t e ds k i nh a v eal o w e rr a t eo fB C C ,b e i n gr a r ei n
those of African descent [5]. This may be due to the
protective eﬀect of melanin pigmentation [4]. Embryonic
fusion planes—the regions of mesenchymal migration and
fusionoftheﬁveprimordialfacialprocessesduringthe5thto
10thweeksofhumandevelopment—havebeenimplicatedin2 Journal of Skin Cancer
thepathogenesis ofbasalcellcarcinoma. NewmanandLeﬀell
[6] reported that basal cell carcinoma was more than four
times more likely to occur on the embryonic fusion plane
than on other regions of the midface.
There is a much greater incidence of BCC in males than
females [4]. This may reﬂect a higher rate of sun exposure
of males because of employment patterns. A population-
based incidence study in Minnesota gave annual incidence
ﬁgures for males and females of 175 and 124 per 100,000,
respectively [7].However, the incidencein women is increas-
ing because of changing fashions in clothing and time spent
outdoors due to recreation patterns or speciﬁc occupations.
It has been suggested that the incidence of persons aﬀected
by BCC is likely to substantially underestimate the true
incidence of this cancer [8]. This is due to the fact that
BCCs are not routinely registered because of their high
frequency and low mortality. In addition, occurrence of
multiple primary tumors within individuals synchronously
or at diﬀerent times is common in BCC patients. Australian
surveysdemonstratedthattheincidenceofpeopletreatedfor
newprimaryBCCswas1.5%in10years[8]andthatover700
persons per 100,000 person years were aﬀected by multiple
BCCs [9].
BCC is more frequent in the elderly, and the incidence of
BCCincreaseswith age.Morethan90%ofBCCsaredetected
in patients aged 60 and older [10–13].
3.ClinicalFeatures
BCC growth is characteristically slow, often evolving for
months to years. The actively growing tissue is at the
periphery of the lesion, with cellular apoptosis and resultant
ulceration in the central region. To treat these lesions,
it is important to eradicate the farthest marginal areas
because these tend to have the most aggressively behaving
cells. Growth may continue for months or even years,
graduallyinvading anddestroyingboneaswellassofttissues.
There is a predilection for invasion along tissue planes, the
periosteum, and nerves. A common theory states that the
embryonic fusion planes, such as the nasolabial fold, are
more susceptible to tumor growth.
4.Diagnosis
Dermoscopy is a noninvasive technique that is known to
increase the diagnostic accuracy of benign versus malignant
pigmented skin lesions [14–19].
Menzies et al. [20] recently proposed a simple dermo-
scopic model for the diagnosis of pigmented BCC, based
on the absence of a pigment network and the presence of
at least one of six positive morphologic features. Positive
dermoscopic features include ulceration, multiple blue-gray
globules,leaﬂikeareas,andtelangiectasia.Furthermore,large
blue-gray ovoid nests have been deﬁned as pigmented ovoid
or elongated areas, larger than globules, and not intimately
connected to the pigmented tumor body. Spoke wheel areas
are an additional parameter appearing as well-circumscribed
radial projections, usually tan, but also blue or gray, meeting
Figure 1: Representative photograph of dermoscopy. Morphologic
features of BCC, such as telangiectasia (arrow), blue-gray globules
(arrowhead), and ulceration, are seen.
at an often darker (dark brown, black, or blue) central axis
(Figure 1)[ 20].
Dermoscopy is frequently able to diﬀerentiate between
BCC and other pigmented skin lesions, such as malignant
melanoma and seborrheic keratosis.
5.Histopathology
BCC is characterized by large nuclei that are oval and
composed mostly of cellular matrix, with little cytoplasm.
There is a higher nucleus-to-cytoplasm ratio in malignant
compared with normal cells. Tumor masses are surrounded
by a peripheral cell layer in which the nuclei form a palisade
or picket fence-type arrangement. Tumors can be classiﬁed
asnodular,superﬁcial,morpheaform,inﬁltrating,metatypic,
and ﬁbroepitheliomaofPinkus[21].Histopathologicaltypes
of BCC have been associated with diﬀerent results and
prognoses.
NodularBCCisthemostfrequentformofBCC,account-
ing for 75% of all cases, being superﬁcial or ulcerated and
often visualized on actinic damaged skin [22]. This lesion
often shows slow growth. Further, around 90% of nodular
BCC lesions are found on the head and neck (Figure 2).
Superﬁcial BCC appears as a plaque or as an erythe-
matous squamous plaque, often found on the trunk and
extremities, although 40% still occurs on the head and neck
[22]( Figure 3).
Morpheaform BCC accounts for approximately 6% of
all BCC, but 95% of these will be located on the head and
neck [22, 23] .I tt e n d st ob em o r ea g g r e s s i v e ,s o m e t i m e s
inﬁltrating deeper in muscles or fat tissue (Figure 4). It
clinically resembles a scar or a small patch. There are no
sites of predilection, and these lesions rarely bleed or get
ulcerated.
Inﬁltrating BCC has been linked to morpheaform or
nodular BCC. Metatypic BCC shows clinical signs of BCC as
well as squamous cell carcinoma (SCC). This subtype tends
to be more aggressive than the other subtypes, and it could
grow and extend as SCC does, with a marked presence ofJournal of Skin Cancer 3
Figure 2: Microphotograph of nodular basal cell carcinoma
(hematoxylin and eosin (HE) staining). Note tumor cells with
largeandhyperchromatic ovoidnucleiandlittlecytoplasmshowing
peripheral palisading.
Figure 3: Microphotograph of superﬁcial basal cell carcinoma (HE
staining). The histologic characteristics of superﬁcial BCC include
buds andirregular proliferationsoftumorcells attached to atrophic
epidermis.
metastasis. Fibroepitheliomao fP i n k u so f t e na p p e a r si nt h e
lumbarand resemblesa ﬁbroepithelial polypusorseborrheic
keratosis [24, 25].
6.Treatment
Common treatments for BCC of the head and neck include
m e t h o d ss u c ha sM o h sm i c r o g r a p h i cs u r g e r y ,s u r g i c a l
excision, liquid nitrogen cryosurgery, and curettage and
electrodessication. Other less frequently employed treatment
modalities include the topical application of 5-ﬂuorouracil
(5-FU)ointment,lasertreatment,radiotherapy,andsystemic
chemotherapy [3] .T h ec h o i c eo ft r e a t m e n ts h o u l db e
determined based on the histological type of lesion, cost,
its size and location, patient age, medical condition of the
patient, treatment availability, and the patient’s wishes. The
aims of any therapy for the treatment of a BCC are to ensure
complete removal, the preservation of function, and a good
cosmetic outcome.
Figure 4: Microphotographs of morpheaform BCC (HE staining).
Morpheaform BCC is characterized by its deep invasion of the
dermis. The overlying skin surface may be atrophic, ulcerated, or
relatively normalin appearance.
6.1. MohsMicrographic Surgery. Mohs micrographic surgery
is well established as the standard of care in many cases
of BCC and squamous cell carcinomas. In 1941, Frederick
Mohs described a surgical technique he had developed for
the staged removal of skin cancer using in situ ﬁxation of
cutaneous tissue using a paste containing zinc chloride [26].
In 1953, he used frozen section without chemical ﬁxation to
excise a recurrent tumor on the eyelid [27]. Tromovitch and
Stegman[28]reportedthefresh tissuetechnique.Theynoted
less pain, discomfort, and anxiety in patients treated with
this technique compared with those treated with chemical
ﬁxation [27, 28]. A detailed map of the tumor site was made
to record the positive margins and to direct the next excision.
Despite advances in techniques, the basic principles have
remained the same in that histologically examined tissue
directing further resection until all margins are clear of
tumor.
T h e r ea r es e v e r a la d v a n t a g e st op e r f o r m i n gM o h sm i c r o -
graphic surgery to the treatment of BCC [29]. First, Mohs
micrographic surgery is the most eﬀective method of
eradicating BCC, with a ﬁve-year cure rate of 99 percent
[30–32]. Another beneﬁt is that Mohs micrographic surgery
spares tissue. Preserving uninvolved tissue is of paramount
importance, especially around the eyes, nose, ears, mouth,
and genitalia. Finally, compared with other surgical tech-
niques involving postoperative repair, the cost of Mohs
micrographic surgery is similar to that of simple excision
in the oﬃce with permanent section postoperative margin
control. Mohs micrographic surgery is less expensive than
excisions with intraoperative margin control with frozen
sections performed in a private oﬃce or in an outpatient
surgical facility [33].
6.2. Surgical Excision. Treatment requires total excision of
the lesion. Surgical excision facilitates pathologic assessment
o ft h et i s s u e[ 34, 35]. The surgical specimen should be
oriented for the pathologist so that the margins can be
examined, allowing the surgeon to verify residual tumor
presence orcompleteexcision. Itis very important toachieve
adequate surgical margins [36]. The margins will depend on4 Journal of Skin Cancer
the size of the lesions, anatomic location, clinical features,
ulceration, and apparent depth of penetration. It has been
common practice to employ a 5mm margin for excision
around BCC [4]. Some authors suggested that surgical
margins oflessthan5mmmight beadequatefornoninvasive
small BCC of the head and neck. Wolf demonstrated that
margins of 4mm were adequatein 95%of nonmorpheaform
BCC less than 2cm in diameter when treated by standard
excision [37]. In addition, Lalloo and Sood [2]r e p o r t e dt h a t
a clinical excision margin of 2mm was adequate for the
treatment of simple, well-demarcated BCCs arising in the
head and neck except for recurrent or morpheaform tumors.
While these margins are adequate for a small BCC whose
histologic subtype is such that the tumor does not warrant
marked lateral or deep excision, it is not an acceptable
margin forlargetumorsorlesionsexhibitingamorpheaform
histology [4].
Silverman et al. [38] analyzed 588 primary and 135
recurrent BCCs treated by surgical excision. Primary-treated
tumors had a cumulative 5-year recurrence rate of 4.8%,
whereas recurrent tumors recurred at a rate of 11.6%,
showing a statistically signiﬁcant diﬀerence. The recurrence
rate is higher for head and neck tumors, with that of the ear
being the highest [38]. There was no signiﬁcant diﬀerence
withregard tothesize oftheprimary lesion.However,Dubin
and Kopf [39] reported that BCC recurrence rates increased
with an expanding lesionsize. Lesions smaller than 2mm did
not recur, lesions 6 to 10mm showed a recurrence rate of
8.8%, and lesions larger than 30mm recurred 23.1% of the
time. As described above, BCC often originates in the skin of
the nose, eyelid, or ear. Surgeons should be familiar with the
structures of these lesions and also with the reconstruction
methods following the surgical resection of deep penetrating
lesions.
6.3. Surgical Excision of Nose Lesions. The nose is a common
location of BCC tumors. Numerous reconstruction methods
have been devised and utilized according to the characteris-
ticsofthedefect.Primary closureisthemost straightforward
method if the defect is small. Although skin grafting is a
simple option, it is not a suitable reconstruction method for
most defects of the nose, because it is diﬃcult to obtain a
goodtextureand colormatch. Alocalﬂapisamorefavorable
reconstruction method for the lower portion of the nose,
where the skin is thickand dense with sebaceous glands [40].
However, if a defect of the nasal tip or the ala is superﬁcial
and too large to cover with a local ﬂap, a full-thickness skin
graft can be used, especially when the skin is relatively thin
and sebaceous glands are sparse [41].
Somelocalﬂapsoftenusedforreconstructionofthenose
are listed as follows.
(1) Nasolabial Flap. The superiorly based nasolabial ﬂap is
useful for defects of the nasal sidewall, ala, and tip, while
the inferiorly based nasolabial ﬂap is useful for defects of
the upper and lower lip, nasal ﬂoor, and columella [41].
An interpolated design is cosmetically desirable. The blood
supply to this ﬂap is excellent due to perforating branches of
the facial artery. The color and texture are excellent matches,
whilethedonorsitescarisacceptableinthenasolabialsulcus.
Using a template defect, a ﬂap is designed on the nasolabial
fold (Figure 5(a)). It is best to make the ﬂap exactly match
the defect size. The medial incision for the ﬂap follows
the nasolabial sulcus, and the lateral incision is placed no
higher than the level of the inferior defect margin. The ﬂap
is elevated in the subcutaneous plane, and the plane goes
deeper as it proceeds superiorly (Figure 5(b)). The ﬂap is
rotated counterclockwise on the right side and transferred to
the defect [41]( Figure 5(c)).
(2) Subcutaneous V-Y Flap. Sliding, subcutaneous V-Y ﬂaps
for the reconstruction of nasal defects have been gaining in
popularity, especially in nasal dorsum reconstruction. The
ﬂaps have also been used in ala nasi reconstructions, for
defects generally limited to less than 1.5cm in diameter
and not involving the rim [42]. The advantages of having
similar tissue in the same operative ﬁeld, with an excellent
blood supply, make the V-Y ﬂap a common choice for nasal
reconstruction. The area of lesion excision and the ﬂap is
marked preoperatively. Once all margins are known to be
clear after tumor excision, the V-Y ﬂap is dissected out and
moved inferiorly on a subcutaneous pedicle to repair the
defect. However, this ﬂap has limitations, particularly in
instances involving the inferior margins of the nose near the
anterior nares. Some notching along the alar rim may occur
and, in younger individuals, would probably be severe. For
repair of the nostril rim, this ﬂap may not be eﬀective. The
higher the defect is located on the nostril away from the rim,
the easier the reconstruction is and the more favorable the
result is [42].
(3) Bilobed Flap. The bilobed nasal ﬂap is a useful and time-
honored technique for reconstructing defects of the nose,
especially defects of the lower third of the nose [41, 43].
The bilobed ﬂap is appropriate for partial-thickness losses
of less than 1.5cm of the lateral aspect of the nose, ala, and
tip area. This ﬂap is essentially a rotation ﬂap divided into
two transposition ﬂaps, with an excellent blood supply from
angular and supraorbital arteries. It recruits skin from the
middorsum and sidewall.
The two ﬂaps have a common base and typically form an
arc of no more than 90–110◦ to avoid tension development
on wound closure (Figure 6(a)). The angle between the
defect and ﬁrst lobe is equal to that between the ﬁrst and
second lobe [41]. The size of the ﬁrst lobe equals that of the
defect,andthesecondlobeis2/3thesize oftheﬁrst lobe.The
primary ﬂap closes the tumor defect, and the secondary ﬂap
is used to close the donor site (Figure 6(b)). The donor site
of the second lobe is primarily closed [43]( Figure 6(c)).
(4) Midline Forehead Skin Flap (Seagull Flap). The midline
forehead skin ﬂap can serve as a cover for any nasal
reconstruction from severe tip and ala loss to a total nasal
defect.Using this ﬂap, estheticand functional reconstruction
can be achieved by creating a nose that blends well with
the face. The seagull-shaped ﬂap is based on one of theJournal of Skin Cancer 5
(a) (b) (c)
Figure 5: Nasolabial ﬂap. (a) A ﬂap is designed on the nasolabialfold. (This is permitted by Japanese Dermatological Association). (b) The
ﬂap is elevated in the subcutaneous plane. The ﬂap is rotated and transferred to the defect. (This is permitted by Japanese Dermatological
Association).(c) The skin defect of nasolabialfold was closed directly. (This is permitted by Japanese DermatologicalAssociation).
(a) (b) (c)
Figure 6: Bilobed ﬂap. (a) Two ﬂaps and surgical margin (5mm) were designed. (b) The primary ﬂap closes the tumor defect, and the
secondary ﬂap is used to close the donor site. (c) The donor site of the second lobe is closed primarily.
supratrochlear vessel bundles. Its vertical axis is placed over
the midline of the forehead, and the wings are designed to lie
in natural transverse creases. Local ﬂaps are turned over and
carried down to the septal support for lining. The forehead
ﬂap is elevated and transposed 180◦ to cover the new nose.
The body of the seagull lies along the bridge, the wings curl
at the ala and turn into the nostril sills, and the seagull head
and neck creates the tip and columella. The forehead donor
site is primarily closed [44].
6.4. Surgical Excision of Eyelid Lesions. The eyelid is also
a common location of BCC tumors. BCC accounts for
90 to 95% of malignant eyelid tumors [45–47]. Regarding
periocular BCC, lower eyelid lesions are the most common,
accounting for up to two-thirds of cases, followed by the
upper eyelid, medial canthus, and lateral canthus [45–47].
Althoughsmall partial-thickness eyeliddefectsmaybeclosed
by simple suture, reconstruction of the lower eyelid after
surgical excision is quite challenging. Salomon et al. [48]
reported that local ﬂaps or full-thickness skin grafts should
be recommended in cases of small- and medium-sized lower
eyelid skin defects. They also reported that the bilobed
ﬂap seemed to be the most appropriate among numerous
possible regional ﬂaps for small- and medium-sized lesions.
The nasolabial ﬂap can also be used for partial or total lower
eyelid reconstruction. The ﬂap is based superiorly, so that
it can easily be rotated to the lower eyelid position. Larger
defects of the medial canthus and adjacent eyelids may be
covered with midline forehead transposition ﬂaps [48]. Full-
thickness palpebral defects ranging from one quarter to one-
half of the lower eyelid may be repaired easily with the use of
a cheek rotation ﬂap [48].
A deep penetrating lesion of the eyelid may invade
the orbit and/or paranasal sinuses. In such cases, orbital6 Journal of Skin Cancer
exenteration and/or resection of the paranasal sinuses may
be required [47–49]. In a study of invasive BCC, Leibovitch
et al. [47] suggested that medial canthus BCC posed a higher
risk of orbital invasion.
6.5. Surgical Excision of Ear Lesions. A wedge excision of
the auricle with a margin is often used for auricular BCC.
The wound edges can be closed without tension in small
lesions. A variety of local ﬂaps for external ear and conchal
reconstruction have been described, and full-thickness skin
grafts (FTSG) have been used as well [50]. Dessy et al. [50]
reported that their ﬁrst choice for the skin graft donor site is
usually the contralateral postauricular area.
After BCC removal from the external auditory canal,
closure of the skin defect of the external auditory canal may
notbeneedediftheunderlyingbone oftheexternalearcanal
is intact. To cover the exposed bone of the external auditory
canal (the skin defect), a skin graft from the postauricular
a r e am a yb eap o s s i b i l i t y .Ac o n c h a ls k i nﬂ a pm a ya l s o
be selected. Based either inferiorly or superiorly, the entire
conchal skin and subcutaneous tissue can be elevated and
transposed across the meatus of the external auditory canal.
The ﬂap donor site is usually closed with a skin graft [51].
6.6. Curettage and Electrodesiccation. Curettage and elec-
trodesiccation (CE) comprise one of the most frequently
used treatment modalities for BCC. The gross tumor is
removed with a curet, and the base is desiccated with a
cautery. The advantages of this technique are that it is
quick and straightforward to learn. The disadvantages are
that, without biopsy and specimen orientation, histological
control is poor or absent, and hypertrophic scars and
hypopigmentation may occur.
It is generally accepted that when eﬀectively treated by
CE experts, cure rates of more than 95% can be expected
for appropriately selected BCC [52]. The types of BCC
that should not be treated by CE include large, inﬁltrating,
morpheaform, and recurrent tumors [52]. Silverman et al.
[53] demonstrated that larger lesions, the diameter, and
high-risk anatomic sites were independent factors aﬀecting
therecurrence rate(RR).Intheirstudy, BCCtreated with CE
at low-risk sites (neck, extremities) had a cumulative 5-year
RR of 3.3% for lesions of any diameter. At medium-risk sites
(scalp, forehead, auricular, and malar), BCCs with diameters
of less than 10mm led to a 5-year RR of 5.3%, whereas
t h o s eo f1 0m mo rl a r g e rh a dah i g h e rR Ro f2 2 . 7 % .A th i g h
risk sites (nose, nasal labial groove, canthi, and ear), BCCs
of less than 6mm in diameter led to a 5-year RR of 4.5%,
whereas those of 6mm or greater were associated with a 5-
year RR of 17.6%. Telfer et al. [52] reported that all primary
BCC patients with tumor of facial sites exhibited a 5-year
cumulativeRR of 1.2%, with 3 recurrences (nose, eyelid, and
preauricular region) in 256 patients.
6.7. Cryotherapy. Cryotherapy is destructive modality that
has been used in the treatment of BCC [54, 55]. Two
freeze-thaw cycles with a tissue temperature of −50
◦Ca r e
required to destroy BCC. Cryotherapy lacks the beneﬁt of
being able to histologically conﬁrm conﬁrmation of tumor
removal. Kuﬂik and Grage [56] reported 99% cure rates
in 628 patients followed for 5 years. August [57] suggested
that cryotherapy should be avoided for the scalp and
nasolabial fold sites because of the high rate of recurrence
of the tumor. Ceilley and del Rosso [58] also mentioned
that aggressive cryotherapy may induce tumor recurrence
because of concealment of the tumor by a ﬁbrous scar.
Nakai et al. [59] reported a case of a nodular BCC with
a skip lesion on the nose, near the nasolabial fold, after
repeated cryotherapy. As for cryotherapy, continuous and
careful observation of the clinical course is required.
6.8. Radiotherapy for Head and Neck BCC Lesions. Radio-
therapy can yield a high cure rate for BCC, and adjunctive
radiotherapy can improve local regional control in cancer
with adverse features such as the presence of perineural
spread, extensive skeletal muscle inﬁltration, bone or car-
tilage invasion, and positive nodal/extranodal spread [60].
Lauritzen et al. [61] reported that the cure rate with
radiotherapy was 92.7% at 5 years in a series of 500BCC
patients. Seegenschmiedt et al. [62] reported that complete
remission was achieved in 99% of patients by 3 months after
treatment, in 127BCC lesions of the head and neck region.
Swanson et al. [63] reported that radiation therapy for BCC
of the medial canthus resulted in a 100% control rate for
positive margins and a 92% control rate for gross disease.
Regarding disadvantage of radiotherapy, radiotherapy
may cause common cutaneous side eﬀects such as acute and
chronic radiation dermatitis [64, 65]. Good initial cosmetic
results can deteriorate with time, such that skin may show
poikiloderma. It is desirable to avoid radiation therapy in
young patients because of the late eﬀects of irradiation [66].
6.9. Photodynamic Therapy (PDT). PDT exerts its local
eﬀects via light-dependent cytotoxicity. The treated area
is exposed to monochromatic light after local or systemic
administration of a chemical photosensitizer, such as methyl
aminolevulinate. The wavelength matches the absorbance
peaks of the photosensitizer used. The photosensitizer
absorbs light energy and then interacts with reactive oxida-
tive species or directly with cellular substrates, resulting in
cell death via apoptosis or necrosis [67]. Good treatment
results of PDT were reported in superﬁcial and nodular
BCCs with response rates of 85%–92% in superﬁcial BCC
and 73%–91% in nodular BCC [68–74]. Although longer
followup studies are required, reported data indicate the
potential of PDT as a noninvasive treatment alternative for
superﬁcial and nodular BCCs [74].
6.10. Hedgehog Signaling Pathway Inhibitors. BCC is asso-
ciated with mutations in components of the hedgehog sig-
naling pathway [75]. Mutations in hedgehog pathway genes,
primarily genes encoding patched homologue 1 (PTCH1)
and smoothened homologue (SMO), occur in BCC. Von
Hoﬀ et al. [76] assessed the safety and pharmacokinetics
of GDC-0449 (vismodegib), a small-molecule inhibitor of
SMO, and responses of metastatic or locally advanced basalJournal of Skin Cancer 7
cell carcinoma to the drug. They reported that 18 of 33
BCC patients had a response to GDC-0449 and that only
one grade 4 adverse event occurred during continuous daily
administration of GDC-0449 for up to 19 months. GDC-
0449 is currently undergoing phase II clinical trials for the
treatment of advanced BCC. Because of its low toxicity and
speciﬁcity for the hedgehog pathway, this drug has potential
advantages compared with conventional chemotherapy and
may also be used in combination treatments [77].
7.BCCSyndrome
Nevoid basal carcinoma syndrome, also referred to as
Gorlin-Goltz syndrome or basal cell carcinoma syndrome,
is a rare autosomal dominant disease showing a genetic
predisposition characterized by multiple BCC [78–81].
Patients with BCC syndrome show multiple abnormal-
ities, none of which are unique to this syndrome [80, 81].
The three abnormalities traditionally considered to be the
most characteristic of the syndrome are BCC, pits on the
palm and sole, and cysts of the jaw. Palmoplantar pits are
small defects in the stratum corneum and may be pink or,
if dirt has accumulated, dark in color. Jaw cysts are often the
ﬁrstdetectableabnormalities,andtheymaybeasymptomatic
and, therefore, diagnosed only radiologically. However, they
also may erode enough bone to cause pain, swelling, and
loss of teeth. A minority of BCCs demonstrate aggressive
behavior and involve the craniofacial bones in nevoid BCC
syndrome. Tabuchi et al. [49] reported a nonfamilial case of
nevoid BCC syndrome with a BCC of the eyelid invading the
ethmoid sinus.
Because the individual abnormalities are not unique to
BCC syndrome patients, it is possible to clinically diagnose
BCC syndrome only when multiple, typical defects are
present. The severity of abnormalities may diﬀer markedly
among members of a single family, and diagnosis certainly
may be diﬃcult in individuals. Generally, the diagnosis is
suggested in a patient with BCC arising at an unexpectedly
early age and in unexpectedly large numbers [49]. The
gene for BCC syndrome has been mapped to chromosome
9q22.3-q31 [82, 83]. Two researchers have independently
demonstrated that BCC syndrome is caused by mutations of
the PATCHED1 (PTCH1) gene [82, 83].
8.Conclusions
BCC is more common than all other cancers, and the
most frequently seen malignancy by most doctors regardless
o ft h e i rs p e c i a l t y .W eh a v et or e c o g n i z eB C Ca n di t s
diﬀerent histologic subtypes, as well as areas in which these
might occur. Several treatment options such as surgical and
nonsurgical are available. Mohs micrographic surgery is the
standard treatment for cases of BCC on the head and neck.
Defects after surgical excision may be repaired by adequate
local ﬂaps. Radiation therapy is also used in the treatment
of primary BCC or in cases where postsurgical margins are
positive for cancer. Adequate treatment promises superior
local disease control for BCC. Thus, doctors in all specialties
need to become more aware of BCC, and accurate and early
diagnoses need to be made by them.
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